CHERRY HILL, N.J., April 29, 2015 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publication at mymsaa.org. This vital resource provides new information on the research findings of the FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions for future research are also presented.
Included in this edition are updates on the currently approved drugs, such as the recent FDA approval of Lemtrada® for relapsing types of MS and the FDA-labeling changes for Tecfidera™. In addition to the exciting research aimed at relapsing forms of MS, a number of studies are now looking into the treatment of progressive forms of MS, which are highlighted in this edition of the MS Research Update for easy and quick identification. This update also features studies in areas such as stem-cell research, therapies for myelin repair and protection, biomarkers, genetic studies, and more.
Today, healthcare professionals and patients have numerous and more complex treatment options to consider. The need for patient education and awareness is crucial. This update and other MSAA resources are valuable tools for anyone looking for treatment information. Read or download the MS Research Update for free or order a printed copy at mymsaa.org.
Please note that this publication was printed prior to the FDA-approval of Glatopa™ (glatiramer acetate injection).
For more information about MS and treatment options, please contact MSAA at (800) 532-7667, or visit mymsaa.org.
The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support. MSAA provides free programs and services, such as: a Helpline with trained specialists; award-winning publications, including MSAA's magazine, The Motivator; MSAA's nationally recognized website (at www.mymsaa.org), featuring award-winning educational videos and research updates; S.E.A.R.C.H.™ program to assist the MS community with learning about different treatment choices; a mobile phone app, My MS Manager™ (named one of the best multiple sclerosis iPhone & Android apps by Healthline.com); a resource database, My MS Resource Locator®; safety and mobility equipment distribution; cooling accessories for heat-sensitive individuals; educational events held across the country; MRI funding; and more. For additional information, please visit www.mymsaa.org or call (800) 532-7667.
About Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS, and can potentially injure the nerves as well. This damage causes reduced communication between the brain and nerve pathways. Common MS symptoms include visual problems, overwhelming fatigue, difficulty with balance and coordination, and various levels of impaired mobility. Many experts estimate that 2.5 million people worldwide have been diagnosed with this disease, and most people with MS are diagnosed between the ages of 15 and 50. MS is not contagious and researchers continue to look for both a cause and a cure.
SOURCE Multiple Sclerosis Association of America